Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Retained Earnings (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Retained Earnings for 15 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings changed 0.0% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $1.2 million, up 100.57% over the prior year.
  • Retained Earnings was $1.2 million for Q3 2025 at Fennec Pharmaceuticals, roughly flat from $1.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $215.6 million in Q3 2023 and bottomed at -$220.8 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$54.0 million, with a median of $1.2 million recorded in 2021.
  • The sharpest move saw Retained Earnings surged 17246.18% in 2023, then plummeted 17867.18% in 2025.
  • Year by year, Retained Earnings stood at $1.2 million in 2021, then changed by 0.0% to $1.2 million in 2022, then plummeted by 17738.37% to -$219.2 million in 2023, then soared by 100.57% to $1.2 million in 2024, then changed by 0.0% to $1.2 million in 2025.
  • Business Quant data shows Retained Earnings for FENC at $1.2 million in Q3 2025, $1.2 million in Q2 2025, and -$220.8 million in Q1 2025.